NewAmsterdam Pharma to Share BROADWAY Kidney, Safety and LDL Particle Data at ACC.26
NewAmsterdam Pharma will present obicetrapib findings at March 28-30 ACC.26, including BROADWAY trial kidney function results, a Phase III safety analysis and LDL particle risk data. The company completed enrollment of over 9,500 patients in its Phase III PREVAIL cardiovascular outcomes trial and granted European rights to Menarini.
1. Conference Presentations
NewAmsterdam Pharma will showcase three digital poster sessions on obicetrapib at the American College of Cardiology Annual Scientific Session in New Orleans from March 28-30, covering renal outcomes, safety data and lipid risk metrics.
2. Kidney Function Preservation
The BROADWAY trial poster highlights that obicetrapib preserved kidney function in high cardiovascular risk patients, indicating potential renal protective benefits of this low-dose oral CETP inhibitor.
3. Phase III Safety Summary
An integrated pooled analysis of Phase III trials demonstrated that obicetrapib’s adverse event profile mirrors placebo, supporting its tolerability as a non-statin LDL-lowering therapy.
4. PREVAIL Enrollment and European Rights
Enrollment in the Phase III PREVAIL cardiovascular outcomes trial surpassed 9,500 randomized patients in April 2024, and Menarini holds exclusive commercialization rights for obicetrapib in Europe.